Short answer
AbbVie Inc (ABBV) filed an 8-K current report with the SEC on July 31, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Filing contains only execution details for AbbVie’s July 31, 2026 Form 8-K.
AbbVie Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing contains only execution details for AbbVie’s July 31, 2026 Form 8-K
- No operating results or financial metrics included in the provided Item 2.02 text
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $16.990B, up 10.2%; adjusted EPS $3.65, up 22.9%, signaling strong operating momentum
- Immunology revenue $8.786B, up 15.1%, led by Skyrizi $5.505B and Rinvoq $2.525B; Humira fell 35.9%
- Neuroscience revenue $3.228B, up 20.3%; oncology declined 1.5% and aesthetics grew only 0.3%, highlighting portfolio concentration
- Proposed $10.9B Apogee acquisition deepens immunology pipeline; expected Q3 close and $0.14 2026 EPS dilution
- 2026 adjusted EPS guidance reduced to $13.87-$14.07, including $0.58 acquired IPR&D impact year-to-date
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AbbVie Inc 8-K filings
Get the next ABBV 8-K as it lands
Follow ABBV for push alerts, or ask the research agent what this filing means.